Ultragenyx Pharmaceutical RARE
NASDAQ RARE
$15.28 +0.43 (+2.93%)
As of: Sep 4, 2026 · 3:59 PM EDT

Ultragenyx Pharmaceutical (RARE) Net Margin Growth (5y) (2021 - 2026)

Analysis

Ultragenyx Pharmaceutical (RARE) Net Margin Growth (5y) (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Ultragenyx Pharmaceutical 1.56 Bn 1.27 Bn 180.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9,777.00
Mar 31, 2026 94.00
Dec 31, 2025 2,850.00
Sep 30, 2025 -2,830.00
Jun 30, 2025 -10,989.00
Mar 31, 2025 21,918.00
Dec 31, 2024 18,278.00
Sep 30, 2024 34,225.00
Jun 30, 2024 32,116.00
Mar 31, 2024 37,561.00
Dec 31, 2023 49,423.00
Sep 30, 2023 57,942.00
Jun 30, 2023 26,456.00
Mar 31, 2023 -44,651.00
Dec 31, 2022 323,553.00
Sep 30, 2022 3.97 Mn
Dec 31, 2021 142.49 Mn
Sep 30, 2021 5.84 Mn
Jun 30, 2021 33.47 Mn